Involvement of xanthine oxidase and paraoxonase 1 in the process of oxidative stress in nonalcoholic fatty liver disease

Wang,Bing; Yang,Rui‑Ning; Zhu,Yue‑Rong; Xing,Ji‑Cheng; Lou,Xiao‑Wei; He,Yu‑Jie; Ding,Qi‑Long; Zhang,Ming‑Yue; Qiu,Hong

doi:10.3892/mmr.2016.6025

Involvement of xanthine oxidase and paraoxonase 1 in the process of oxidative stress in nonalcoholic fatty liver disease

Authors:
- Bing Wang
- Rui‑Ning Yang
- Yue‑Rong Zhu
- Ji‑Cheng Xing
- Xiao‑Wei Lou
- Yu‑Jie He
- Qi‑Long Ding
- Ming‑Yue Zhang
- Hong Qiu
View Affiliations

Affiliations: Department of Clinical Laboratory, PLA 81 Hospital, Nanjing, Jiangsu 210002, P.R. China, Experimental and Teaching Center of Medical Basis for Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China, Department of Blood Transfusion, Central Hospital of Nanyang, Nanyang, Henan 473000, P.R. China
Published online on: December 12, 2016 https://doi.org/10.3892/mmr.2016.6025
Pages: 387-395

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Xanthine oxidase (XOD) and paraoxonase 1 (PON1) are important enzymes in redox reactions in vivo, and are predominantly synthesized by the liver. The aim of the present study was to investigate the redox state in nonalcoholic fatty liver disease, and determine the association between the activities of XOD and PON1 and the severity of NAFLD. Sprague‑Dawley rats were randomly divided into control, model and α‑lipoic acid (high and low dose) groups. The rats in the NAFLD model were induced by feeding a high fat diet for 12 weeks and the in vitro cell model of hepatocyte steatosis was induced by treating L‑02 cells with oleic acid for 24 h. The body weight, liver function, lipid and oxidative stress indices, and histological features of the liver were examined in the rats. Compared with the control group, the rats in the NAFLD model group showed impaired liver function, lipid disorders and damage from oxidative stress. The serum activity of XOD increased significantly from the 4th week and was markedly higher, compared with that in the control group, reaching a peak in the 12th week. The activity of PON1 was negatively correlated with that of XOD. Compared with the control cells, the activity of XOD and levels of free‑fatty acids were significantly higher, and the activity of PON1 was significantly lower in the NAFLD L‑02 cell model. All the above indicators were significantly improved by treatment with the antioxidant, α‑lipoic acid. The activities of XOD and PON1 may be promising as markers in a noninvasive approach for detecting the severity of NAFLD clinically. α‑lipoic acid had protective effects on the NAFLD rats, and the potential mechanism may be associated with the inhibition of oxidative stress and lipid peroxidation.

View Figures

View References

1	Singer C, Stancu P, Coşoveanu S and Botu A: Non-alcoholic fatty liver disease in children. Curr Health Sci J. 40:170–176. 2014.PubMed/NCBI
2	Masarone M, Federico A, Abenavoli L, Loguercio C and Persico M: Non alcoholic Fatty liver: Epidemiology and natural history. Rev Recent Clin Trials. 9:126–133. 2014.PubMed/NCBI
3	Wang FS, Fan JG, Zhang Z, Gao B and Wang HY: The global burden of liver disease: The major impact of China. Hepatology. 60:2099–2108. 2014. View Article : Google Scholar : PubMed/NCBI
4	Mehta K, Van Thiel DH, Shah N and Mobarhan S: Nonalcoholic fatty liver disease: Pathogenesis and the role of antioxidants. Nutr Rev. 60:289–293. 2002. View Article : Google Scholar : PubMed/NCBI
5	Guo J, Ren W, Li A, Ding Y, Guo W, Su D, Hu C, Xu K, Chen H, Xu X, et al: Fat mass and obesity-associated gene enhances oxidative stress and lipogenesis in nonalcoholic fatty liver disease. Dig Dis Sci. 58:1004–1009. 2013. View Article : Google Scholar : PubMed/NCBI
6	Surapaneni KM and Jainu M: Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis. J Physiol Pharmacol. 65:67–74. 2014.PubMed/NCBI
7	Doehner W and Landmesser U: Xanthine oxidase and uric acid in cardiovascular disease: Clinical impact and therapeutic options. Semin Nephrol. 31:433–440. 2011. View Article : Google Scholar : PubMed/NCBI
8	Sumida Y, Niki E, Naito Y and Yoshikawa T: Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res. 47:869–880. 2013. View Article : Google Scholar : PubMed/NCBI
9	Mackness M and Mackness B: Targeting paraoxonase-1 in atherosclerosis. Expert Opin Ther Targets. 17:829–837. 2013. View Article : Google Scholar : PubMed/NCBI
10	Wang M, Lang X, Cui S, Zou L, Cao J, Wang S and Wu X: Quantitative assessment of the influence of paraoxonase 1 activity and coronary heart disease risk. DNA Cell Biol. 31:975–982. 2012. View Article : Google Scholar : PubMed/NCBI
11	Manning PJ, Jong SA, Ryalls AR and Sutherland WH: Paraoxonase 1 activity in chylomicrons and VLDL: The effect of type 2 diabetes and meals rich in saturated fat and oleic acid. Lipids. 47:259–267. 2012. View Article : Google Scholar : PubMed/NCBI
12	Ferre N, Marsillach J, Camps J, Mackness B, Mackness M, Riu F, Coll B, Tous M and Joven J: Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol. 45:51–59. 2006. View Article : Google Scholar : PubMed/NCBI
13	Marsillach J, Camps J, Ferré N, Beltran R, Rull A, Mackness B, Mackness M and Joven J: Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterol. 9:32009. View Article : Google Scholar : PubMed/NCBI
14	Samy W and Hassanian MA: Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab J Gastroenterol. 12:80–85. 2011. View Article : Google Scholar : PubMed/NCBI
15	Karsen H, Binici I, Sunnetcioglu M, Baran AI, Ceylan MR, Selek S and Celik H: Association of paraoxonase activity and atherosclerosis in patients with chronic hepatitis B. Afr Health Sci. 12:114–118. 2012.PubMed/NCBI
16	Mingyue Z, Bing W, Qilong D, Ruining Y and Hong Q: Study on the relationship between xanthine oxidase paraoxonase-1 and occurrence and development of nonalcoholic fatty liver disease. Chinese Hepatology. 19:323–328. 2014.
17	Tuyama AC and Chang CY: Non-alcoholic fatty liver disease. J Diabetes. 4:266–280. 2012. View Article : Google Scholar : PubMed/NCBI
18	Day CP and James OF: Steatohepatitis: A tale of two ‘hits’? Gastroenterology. 114:842–845. 1998. View Article : Google Scholar : PubMed/NCBI
19	Hijona E, Hijona L, Arenas JI and Bujanda L: Inflammatory mediators of hepatic steatosis. Mediators Inflamm. 2010:8374192010.PubMed/NCBI
20	Stiuso P, Scognamiglio I, Murolo M, Ferranti P, De Simone C, Rizzo MR, Tuccillo C, Caraglia M, Loguercio C and Federico A: Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: A pilot study. Oxid Med Cell Longev. 2014:1692162014.PubMed/NCBI
21	Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F and Karakok M: Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 34:57–62. 2004.PubMed/NCBI
22	Parks DA and Granger DN: Xanthine oxidase: Biochemistry, distribution and physiology. Acta Physiol Scand Suppl. 548:87–99. 1986.PubMed/NCBI
23	Sarnesto A, Linder N and Raivio KO: Organ distribution and molecular forms of human xanthine dehydrogenase/xanthine oxidase protein. Lab Invest. 74:48–56. 1996.PubMed/NCBI
24	Morita M, Ishida N, Uchiyama K, Yamaguchi K, Itoh Y, Shichiri M, Yoshida Y, Hagihara Y, Naito Y, Yoshikawa T and Niki E: Fatty liver induced by free radicals and lipid peroxidation. Free Radic Res. 46:758–765. 2012. View Article : Google Scholar : PubMed/NCBI
25	Rodrigo L, Hernández AF, López-Caballero JJ, Gil F and Pla A: Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact. 137:123–137. 2001. View Article : Google Scholar : PubMed/NCBI
26	Karlsson H, Kontush A and James RW: Functionality of HDL: Antioxidation and detoxifying effects. Handb Exp Pharmacol. 224:207–228. 2015. View Article : Google Scholar : PubMed/NCBI
27	Mackness MI, Arrol S and Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286:152–154. 1991. View Article : Google Scholar : PubMed/NCBI
28	Marsillach J, Camps J, Beltran-Debón R, Rull A, Aragones G, Maestre-Martínez C, Sabench F, Hernández M, Castillo DD, Joven J, et al: Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. Eur J Clin Invest. 41:308–314. 2011. View Article : Google Scholar : PubMed/NCBI
29	Gür M, Çaylı M, Uçar H, Elbasan Z, Şahin DY, Gözükara MY, Selek Ş, Koyunsever NY, Şeker T, Türkoğlu C, et al: Paraoxonase (PON1) activity in patients with subclinical thoracic aortic atherosclerosis. Int J Cardiovasc Imaging. 30:889–895. 2014. View Article : Google Scholar : PubMed/NCBI
30	Fu AL and Wu SP: Single intravenous injection of plasmid DNA encoding human paraoxonase-1 inhibits hyperlipidemia in rats. Biochem Biophys Res Commun. 397:257–262. 2010. View Article : Google Scholar : PubMed/NCBI
31	Rosenblat M, Vaya J, Shih D and Aviram M: Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: A possible role for lysophosphatidylcholine. Atherosclerosis. 179:69–77. 2005. View Article : Google Scholar : PubMed/NCBI
32	Gorąca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E and Skibska B: Lipoic acid-biological activity and therapeutic potential. Pharmacol Rep. 63:849–858. 2011. View Article : Google Scholar : PubMed/NCBI
33	Rahimifard M, Navaei-Nigjeh M, Baeeri M, Maqbool F and Abdollahi M: Multiple protective mechanisms of alpha-lipoic acid in oxidation, apoptosis and inflammation against hydrogen peroxide induced toxicity in human lymphocytes. Mol Cell Biochem. 403:179–186. 2015. View Article : Google Scholar : PubMed/NCBI
34	Park S, Karunakaran U, Jeoung NH, Jeon JH and Lee IK: Physiological effect and therapeutic application of alpha lipoic acid. Curr Med Chem. 21:3636–3645. 2014. View Article : Google Scholar : PubMed/NCBI
35	Carrier B, Wen S, Zigouras S, Browne RW, Li Z, Patel MS, Williamson DL and Rideout TC: Alpha-lipoic acid reduces LDL-particle number and PCSK9 concentrations in high-fat fed obese Zucker rats. PLoS One. 9:e908632014. View Article : Google Scholar : PubMed/NCBI
36	Huerta AE, Navas-Carretero S, Prieto-Hontoria PL, Martínez JA and Moreno-Aliaga MJ: Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss. Obesity (Silver Spring). 23:313–321. 2015. View Article : Google Scholar : PubMed/NCBI
37	Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J and Berg T: NASH Study Group: High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double-blind, randomized, placebo-controlled trial. Hepatology. 52:472–479. 2010. View Article : Google Scholar : PubMed/NCBI
38	Perra A, Pibiri M, Sulas P, Simbula G, Ledda-Columbano GM and Columbano A: Alpha-lipoic acid promotes the growth of rat hepatic pre-neoplastic lesions in the choline-deficient model. Carcinogenesis. 29:161–168. 2008.PubMed/NCBI